S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
FB   197.93 (+0.21%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
Log in

Abbott Laboratories Stock Price, Forecast & Analysis (NYSE:ABT)

$83.68
-0.21 (-0.25 %)
(As of 11/21/2019 04:00 PM ET)
Today's Range
$82.36
Now: $83.68
$83.80
50-Day Range
$78.83
MA: $82.40
$85.71
52-Week Range
$65.44
Now: $83.68
$88.76
Volume4.34 million shs
Average Volume5.31 million shs
Market Capitalization$147.98 billion
P/E Ratio29.06
Dividend Yield1.53%
Beta1.13
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP00282410
CIK1800
Phone224-667-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.58 billion
Cash Flow$4.69 per share
Book Value$17.49 per share

Profitability

Net Income$2.37 billion

Miscellaneous

Employees103,000
Outstanding Shares1,768,456,000
Market Cap$147.98 billion
Next Earnings Date1/22/2020 (Estimated)
OptionableOptionable

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.


Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Thursday, September 12th. Investors of record on Tuesday, October 15th will be given a dividend of $0.32 per share on Friday, November 15th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.53%. The ex-dividend date is Friday, October 11th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) posted its quarterly earnings data on Wednesday, October, 16th. The healthcare product maker reported $0.84 EPS for the quarter, hitting the Zacks' consensus estimate of $0.84. The healthcare product maker had revenue of $8.08 billion for the quarter, compared to the consensus estimate of $8.10 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 17.65%. The firm's quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.75 earnings per share. View Abbott Laboratories' Earnings History.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, January 22nd 2020. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories issued an update on its FY19 earnings guidance on Wednesday, October, 16th. The company provided earnings per share (EPS) guidance of $3.23-3.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.24.

What price target have analysts set for ABT?

17 equities research analysts have issued twelve-month target prices for Abbott Laboratories' stock. Their forecasts range from $68.00 to $98.00. On average, they expect Abbott Laboratories' stock price to reach $87.22 in the next year. This suggests a possible upside of 4.2% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

What is the consensus analysts' recommendation for Abbott Laboratories?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

Has Abbott Laboratories been receiving favorable news coverage?

Press coverage about ABT stock has been trending positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Abbott Laboratories earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news coverage about the healthcare product maker a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Abbott Laboratories.

Are investors shorting Abbott Laboratories?

Abbott Laboratories saw a decrease in short interest in October. As of October 31st, there was short interest totalling 16,670,000 shares, a decrease of 5.8% from the September 30th total of 17,690,000 shares. Based on an average daily trading volume, of 4,520,000 shares, the short-interest ratio is currently 3.7 days. Approximately 1.0% of the company's stock are sold short. View Abbott Laboratories' Current Options Chain.

Who are some of Abbott Laboratories' key competitors?

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Pfizer (PFE), Micron Technology (MU), NVIDIA (NVDA), Walt Disney (DIS), CA (CA) and Intel (INTC).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:
  • Mr. Miles D. White M.B.A., Chairman & CEO (Age 64)
  • Mr. Robert B. Ford, Pres & COO (Age 45)
  • Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
  • Mr. Stephen R. Fussell, Exec. VP of HR (Age 62)

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by many different of institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (1.80%), Sumitomo Mitsui Trust Holdings Inc. (0.39%), Diamond Hill Capital Management Inc. (0.36%), California Public Employees Retirement System (0.23%), Rhumbline Advisers (0.19%) and Russell Investments Group Ltd. (0.15%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Which institutional investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Coho Partners Ltd., Massachusetts Financial Services Co. MA, Columbus Circle Investors, Sawgrass Asset Management LLC, Montag & Caldwell LLC, Sector Gamma AS, State of New Jersey Common Pension Fund D and BB&T Securities LLC. Company insiders that have sold Abbott Laboratories company stock in the last year include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Which institutional investors are buying Abbott Laboratories stock?

ABT stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Strs Ohio, Assenagon Asset Management S.A., State of Tennessee Treasury Department, Bartlett & Co. LLC, State of Alaska Department of Revenue, Banco Santander S.A. and First Trust Advisors LP. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $83.68.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $147.98 billion and generates $30.58 billion in revenue each year. The healthcare product maker earns $2.37 billion in net income (profit) each year or $2.88 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is http://www.abbott.com/.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.


MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  769 (Vote Outperform)
Underperform Votes:  636 (Vote Underperform)
Total Votes:  1,405
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel